Published in PLoS Pathog on March 20, 2009
A highly conserved neutralizing epitope on group 2 influenza A viruses. Science (2011) 5.66
Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J Clin Invest (2010) 4.62
Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses. Science (2012) 3.53
HIV-1 and influenza antibodies: seeing antigens in new ways. Nat Immunol (2009) 2.80
Cross-neutralization of influenza A viruses mediated by a single antibody loop. Nature (2012) 2.44
Wide prevalence of heterosubtypic broadly neutralizing human anti-influenza A antibodies. Clin Infect Dis (2011) 2.12
Naturally occurring human monoclonal antibodies neutralize both 1918 and 2009 pandemic influenza A (H1N1) viruses. J Virol (2009) 1.94
Influenza: the once and future pandemic. Public Health Rep (2010) 1.65
A recurring motif for antibody recognition of the receptor-binding site of influenza hemagglutinin. Nat Struct Mol Biol (2013) 1.60
Enzyme-linked immunosorbent assay for detection of filovirus species-specific antibodies. Clin Vaccine Immunol (2010) 1.59
Broadly neutralizing antibodies against influenza virus and prospects for universal therapies. Curr Opin Virol (2012) 1.54
Distinct germinal center selection at local sites shapes memory B cell response to viral escape. J Exp Med (2015) 1.50
Pandemic H1N1 Influenza Infection and Vaccination in Humans Induces Cross-Protective Antibodies that Target the Hemagglutinin Stem. Front Immunol (2012) 1.50
Monoclonal antibody-based therapies for microbial diseases. Vaccine (2009) 1.47
Structural insights into key sites of vulnerability on HIV-1 Env and influenza HA. Immunol Rev (2012) 1.44
Continuing challenges in influenza. Ann N Y Acad Sci (2014) 1.43
Naturally occurring antibodies in humans can neutralize a variety of influenza virus strains, including H3, H1, H2, and H5. J Virol (2011) 1.42
Broadly neutralizing antibodies against influenza viruses. Antiviral Res (2013) 1.29
Cooperativity between CD8+ T cells, non-neutralizing antibodies, and alveolar macrophages is important for heterosubtypic influenza virus immunity. PLoS Pathog (2013) 1.28
Heterosubtypic antibody recognition of the influenza virus hemagglutinin receptor binding site enhanced by avidity. Proc Natl Acad Sci U S A (2012) 1.22
Human monoclonal antibodies to pandemic 1957 H2N2 and pandemic 1968 H3N2 influenza viruses. J Virol (2012) 1.20
Heterosubtype neutralizing responses to influenza A (H5N1) viruses are mediated by antibodies to virus haemagglutinin. PLoS One (2009) 1.20
Hallmarks of CD4 T cell immunity against influenza. J Intern Med (2011) 1.19
Influenza human monoclonal antibody 1F1 interacts with three major antigenic sites and residues mediating human receptor specificity in H1N1 viruses. PLoS Pathog (2012) 1.19
A 27-amino-acid deletion in the neuraminidase stalk supports replication of an avian H2N2 influenza A virus in the respiratory tract of chickens. J Virol (2010) 1.18
H5N1 vaccines in humans. Virus Res (2013) 1.16
A human antibody recognizing a conserved epitope of H5 hemagglutinin broadly neutralizes highly pathogenic avian influenza H5N1 viruses. J Virol (2012) 1.15
A cross-reactive neutralizing monoclonal antibody protects mice from H5N1 and pandemic (H1N1) 2009 virus infection. Antiviral Res (2010) 1.07
The Ras-PI3K signaling pathway is involved in clathrin-independent endocytosis and the internalization of influenza viruses. PLoS One (2011) 1.05
Universal immunity to influenza must outwit immune evasion. Front Microbiol (2014) 1.03
Structural characterization of viral epitopes recognized by broadly cross-reactive antibodies. Curr Top Microbiol Immunol (2015) 1.02
Identification and structural characterization of a broadly neutralizing antibody targeting a novel conserved epitope on the influenza virus H5N1 hemagglutinin. J Virol (2012) 1.00
An influenza A/H1N1/2009 hemagglutinin vaccine produced in Escherichia coli. PLoS One (2010) 0.97
Intranasal delivery of an IgA monoclonal antibody effective against sublethal H5N1 influenza virus infection in mice. Clin Vaccine Immunol (2010) 0.96
Specific recognition of influenza A/H1N1/2009 antibodies in human serum: a simple virus-free ELISA method. PLoS One (2010) 0.94
Conserved neutralizing epitope at globular head of hemagglutinin in H3N2 influenza viruses. J Virol (2014) 0.91
Type-I interferon is critical for FasL expression on lung cells to determine the severity of influenza. PLoS One (2013) 0.91
Identification of a highly conserved H1 subtype-specific epitope with diagnostic potential in the hemagglutinin protein of influenza A virus. PLoS One (2011) 0.90
Comparison of antiviral activity between IgA and IgG specific to influenza virus hemagglutinin: increased potential of IgA for heterosubtypic immunity. PLoS One (2014) 0.87
Vaccination of monoglycosylated hemagglutinin induces cross-strain protection against influenza virus infections. Proc Natl Acad Sci U S A (2014) 0.87
Unraveling of a neutralization mechanism by two human antibodies against conserved epitopes in the globular head of H5 hemagglutinin. J Virol (2012) 0.86
Human monoclonal antibodies broadly neutralizing against influenza B virus. PLoS Pathog (2013) 0.86
Human monoclonal antibodies targeting the haemagglutinin glycoprotein can neutralize H7N9 influenza virus. Nat Commun (2015) 0.85
Glycan masking of hemagglutinin for adenovirus vector and recombinant protein immunizations elicits broadly neutralizing antibodies against H5N1 avian influenza viruses. PLoS One (2014) 0.84
Targets for the induction of protective immunity against influenza a viruses. Viruses (2010) 0.82
Significant impact of sequence variations in the nucleoprotein on CD8 T cell-mediated cross-protection against influenza A virus infections. PLoS One (2010) 0.82
Two Escape Mechanisms of Influenza A Virus to a Broadly Neutralizing Stalk-Binding Antibody. PLoS Pathog (2016) 0.82
Pandemic influenza 1918 H1N1 and 1968 H3N2 DNA vaccines induce cross-reactive immunity in ferrets against infection with viruses drifted for decades. Influenza Other Respir Viruses (2010) 0.81
The neuraminidases of MDCK grown human influenza A(H3N2) viruses isolated since 1994 can demonstrate receptor binding. Virol J (2015) 0.80
A broadly neutralizing human monoclonal antibody directed against a novel conserved epitope on the influenza virus H3 hemagglutinin globular head. J Virol (2014) 0.80
Rapid Generation of Human-Like Neutralizing Monoclonal Antibodies in Urgent Preparedness for Influenza Pandemics and Virulent Infectious Diseases. PLoS One (2013) 0.80
Prospects of HA-based universal influenza vaccine. Biomed Res Int (2015) 0.79
Heterosubtypic antiviral activity of hemagglutinin-specific antibodies induced by intranasal immunization with inactivated influenza viruses in mice. PLoS One (2013) 0.79
An anti-H5N1 influenza virus FcDART antibody is a highly efficacious therapeutic agent and prophylactic against H5N1 influenza virus infection. J Virol (2015) 0.78
Cross-protection of newly emerging HPAI H5 viruses by neutralizing human monoclonal antibodies: A viable alternative to oseltamivir. MAbs (2016) 0.77
Heads, stalks and everything else: how can antibodies eradicate influenza as a human disease? Curr Opin Immunol (2016) 0.77
Receptor-binding domains of spike proteins of emerging or re-emerging viruses as targets for development of antiviral vaccines. Emerg Microbes Infect (2012) 0.77
Structural basis for the development of avian virus capsids that display influenza virus proteins and induce protective immunity. J Virol (2014) 0.76
Fcγ-receptor IIa-mediated Src Signaling Pathway is Essential for the Antibody-Dependent Enhancement of Ebola Virus Infection. PLoS Pathog (2016) 0.75
Does exposure to poultry and wild fowl confer immunity to H5N1? Chin Med J (Engl) (2014) 0.75
Diversity of the murine antibody response targeting influenza A(H1N1pdm09) hemagglutinin. Virology (2014) 0.75
Study of immunogenicity of recombinant proteins based on hemagglutinin and neuraminidase conservative epitopes of influenza A virus. Med Sci Monit Basic Res (2013) 0.75
The Analysis of B-Cell Epitopes of Influenza Virus Hemagglutinin. Acta Naturae (2016) 0.75
Generation of monoclonal pan-hemagglutinin antibodies for the quantification of multiple strains of influenza. PLoS One (2017) 0.75
In Vivo Production of Monoclonal Antibodies by Gene Transfer via Electroporation Protects against Lethal Influenza and Ebola Infections. Mol Ther Methods Clin Dev (2017) 0.75
Diversity of Functionally Permissive Sequences in the Receptor-Binding Site of Influenza Hemagglutinin. Cell Host Microbe (2017) 0.75
Evolution and ecology of influenza A viruses. Microbiol Rev (1992) 39.99
Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 A resolution. Nature (1981) 24.17
Universal primer set for the full-length amplification of all influenza A viruses. Arch Virol (2001) 21.17
Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu Rev Biochem (2000) 19.03
Structural identification of the antibody-binding sites of Hong Kong influenza haemagglutinin and their involvement in antigenic variation. Nature (1981) 15.85
The antigenic structure of the influenza virus A/PR/8/34 hemagglutinin (H1 subtype). Cell (1982) 12.44
Characterization of a novel influenza A virus hemagglutinin subtype (H16) obtained from black-headed gulls. J Virol (2005) 10.77
Early alterations of the receptor-binding properties of H1, H2, and H3 avian influenza virus hemagglutinins after their introduction into mammals. J Virol (2000) 8.28
The structure and receptor binding properties of the 1918 influenza hemagglutinin. Science (2004) 7.74
VERIFY3D: assessment of protein models with three-dimensional profiles. Methods Enzymol (1997) 6.71
A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains. J Virol (1993) 6.26
Influenza A virus M2 protein: monoclonal antibody restriction of virus growth and detection of M2 in virions. J Virol (1988) 5.31
Eight-plasmid system for rapid generation of influenza virus vaccines. Vaccine (2002) 4.45
Glycan topology determines human adaptation of avian H5N1 virus hemagglutinin. Nat Biotechnol (2008) 4.37
Tools for comparative protein structure modeling and analysis. Nucleic Acids Res (2003) 3.68
Mucosal delivery of inactivated influenza vaccine induces B-cell-dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infection. J Virol (2001) 3.05
The receptor-binding and membrane-fusion properties of influenza virus variants selected using anti-haemagglutinin monoclonal antibodies. EMBO J (1987) 3.03
Biological activity of monoclonal antibodies to operationally defined antigenic regions on the hemagglutinin molecule of A/Seal/Massachusetts/1/80 (H7N7) influenza virus. Virology (1982) 2.78
Quantitative biochemical rationale for differences in transmissibility of 1918 pandemic influenza A viruses. Proc Natl Acad Sci U S A (2008) 2.77
Structure of antigenic sites on the haemagglutinin molecule of H5 avian influenza virus and phenotypic variation of escape mutants. J Gen Virol (2002) 2.63
Binding of the influenza A virus to cell-surface receptors: structures of five hemagglutinin-sialyloligosaccharide complexes determined by X-ray crystallography. Virology (1997) 2.51
A complex of influenza hemagglutinin with a neutralizing antibody that binds outside the virus receptor binding site. Nat Struct Biol (1999) 2.47
The PDBFINDER database: a summary of PDB, DSSP and HSSP information with added value. Comput Appl Biosci (1996) 2.46
Epitope mapping of the hemagglutinin molecule of a highly pathogenic H5N1 influenza virus by using monoclonal antibodies. J Virol (2007) 2.39
Variation and infectivity neutralization in influenza. Immunology (2006) 2.23
X-ray structure of the hemagglutinin of a potential H3 avian progenitor of the 1968 Hong Kong pandemic influenza virus. Virology (2003) 2.23
Passive immunoprophylaxis and therapy with humanized monoclonal antibody specific for influenza A H5 hemagglutinin in mice. Respir Res (2006) 2.15
Influenza Virus Database (IVDB): an integrated information resource and analysis platform for influenza virus research. Nucleic Acids Res (2006) 2.14
Induction of heterosubtypic immunity to influenza virus by intranasal immunization. J Virol (2007) 2.06
Passively transferred monoclonal antibody to the M2 protein inhibits influenza A virus replication in mice. J Virol (1990) 1.82
Intranasal immunization with formalin-inactivated virus vaccine induces a broad spectrum of heterosubtypic immunity against influenza A virus infection in mice. Vaccine (2003) 1.78
Structural differences among hemagglutinins of influenza A virus subtypes are reflected in their antigenic architecture: analysis of H9 escape mutants. J Virol (2004) 1.73
Protection against the mouse-adapted A/FM/1/47 strain of influenza A virus in mice by a monoclonal antibody with cross-neutralizing activity among H1 and H2 strains. J Virol (1994) 1.72
Antigenic structure of the haemagglutinin of human influenza A/H2N2 virus. J Gen Virol (2001) 1.71
Avian and human receptor binding by hemagglutinins of influenza A viruses. Glycoconj J (2006) 1.66
Prevention and treatment of bronchopneumonia in mice caused by mouse-adapted variant of avian H5N2 influenza A virus using monoclonal antibody against conserved epitope in the HA stem region. Arch Virol (2000) 1.61
Heterosubtypic immunity to influenza A virus infection requires B cells but not CD8+ cytotoxic T lymphocytes. J Infect Dis (2000) 1.61
Influenza virus-specific cytotoxic T lymphocytes: a correlate of protection and a basis for vaccine development. Curr Opin Biotechnol (2007) 1.60
Isolation of cross-reactive, subtype-specific monoclonal antibodies against influenza virus HA1 and HA2 hemagglutinin subunits. Arch Virol (1987) 1.31
Monoclonal antibodies recognizing EVETPIRN epitope of influenza A virus M2 protein could protect mice from lethal influenza A virus challenge. Immunol Lett (2004) 1.26
Epitopes required for antibody-dependent enhancement of Ebola virus infection. J Infect Dis (2007) 1.16
Immunogenic properties of the small chain HA2 of the haemagglutinin of influenza viruses. J Gen Virol (1984) 1.12
Monoclonal antibodies to glycopolypeptides HA1 and HA2 of influenza virus haemagglutinin. Acta Virol (1987) 1.10
Antibodies specific to the HA2 glycopolypeptide of influenza A virus haemagglutinin with fusion-inhibition activity contribute to the protection of mice against lethal infection. J Gen Virol (2007) 1.07
Binding of the hemagglutinin from human or equine influenza H3 viruses to the receptor is altered by substitutions at residue 193. Arch Virol (2004) 1.05
Evaluation of monoclonal antibodies for subtyping of currently circulating human type A influenza viruses. J Clin Microbiol (1997) 1.00
Conservation of epitopes recognized by monoclonal antibodies against the separated subunits of influenza hemagglutinin among type A viruses of the same and different subtypes. Arch Virol (1991) 0.89
In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature (2009) 14.59
Avian flu: isolation of drug-resistant H5N1 virus. Nature (2005) 6.66
Enhanced virulence of influenza A viruses with the haemagglutinin of the 1918 pandemic virus. Nature (2004) 6.11
Architecture of ribonucleoprotein complexes in influenza A virus particles. Nature (2006) 4.52
Characterization of H7N9 influenza A viruses isolated from humans. Nature (2013) 3.71
Ebola virus VP40 drives the formation of virus-like filamentous particles along with GP. J Virol (2002) 3.62
Hierarchy among viral RNA (vRNA) segments in their role in vRNA incorporation into influenza A virions. J Virol (2006) 2.70
Contributions of two nuclear localization signals of influenza A virus nucleoprotein to viral replication. J Virol (2006) 2.60
Studies of H5N1 influenza virus infection of pigs by using viruses isolated in Vietnam and Thailand in 2004. J Virol (2005) 2.56
Importance of both the coding and the segment-specific noncoding regions of the influenza A virus NS segment for its efficient incorporation into virions. J Virol (2005) 2.45
Molecular determinants of Ebola virus virulence in mice. PLoS Pathog (2006) 2.44
Influenza: emergence and control. J Virol (2004) 2.31
Tyro3 family-mediated cell entry of Ebola and Marburg viruses. J Virol (2006) 2.24
Polymorphisms and the differential antiviral activity of the chicken Mx gene. Genome Res (2002) 2.18
Characterization of a human H5N1 influenza A virus isolated in 2003. J Virol (2005) 2.09
Production of novel ebola virus-like particles from cDNAs: an alternative to ebola virus generation by reverse genetics. J Virol (2004) 2.09
Ebola virus VP40 late domains are not essential for viral replication in cell culture. J Virol (2005) 1.97
Immune parameters correlate with protection against ebola virus infection in rodents and nonhuman primates. Sci Transl Med (2012) 1.83
Intranasal immunization with formalin-inactivated virus vaccine induces a broad spectrum of heterosubtypic immunity against influenza A virus infection in mice. Vaccine (2003) 1.78
Concern Serological evidence of Ebola virus infection in Indonesian orangutans. PLoS One (2012) 1.75
Predicting the antigenic structure of the pandemic (H1N1) 2009 influenza virus hemagglutinin. PLoS One (2010) 1.64
Replication and transmission of influenza viruses in Japanese quail. Virology (2003) 1.64
Assembly and budding of Ebolavirus. PLoS Pathog (2006) 1.62
Enzyme-linked immunosorbent assay for detection of filovirus species-specific antibodies. Clin Vaccine Immunol (2010) 1.59
Tetraspanin CD151 protects against pulmonary fibrosis by maintaining epithelial integrity. Am J Respir Crit Care Med (2012) 1.55
Protective efficacy of neutralizing monoclonal antibodies in a nonhuman primate model of Ebola hemorrhagic fever. PLoS One (2012) 1.54
Characterization of H5N1 highly pathogenic avian influenza virus strains isolated from migratory waterfowl in Mongolia on the way back from the southern Asia to their northern territory. Virology (2010) 1.48
Neurotropism of the 1997 Hong Kong H5N1 influenza virus in mice. Vet Microbiol (2003) 1.47
Pathologic findings of initial biopsies reflect the outcomes of membranous nephropathy. Kidney Int (2004) 1.46
Influenza A virus polymerase inhibits type I interferon induction by binding to interferon beta promoter stimulator 1. J Biol Chem (2010) 1.43
The development and characterization of H5 influenza virus vaccines derived from a 2003 human isolate. Vaccine (2005) 1.42
Resistance to influenza A virus infection in transformed cell lines expressing an anti-PB2 monoclonal antibody. Vet J (2013) 1.39
The quail and chicken intestine have sialyl-galactose sugar chains responsible for the binding of influenza A viruses to human type receptors. Glycobiology (2007) 1.37
Generation of velogenic Newcastle disease viruses from a nonpathogenic waterfowl isolate by passaging in chickens. Virology (2002) 1.37
PB2 protein of a highly pathogenic avian influenza virus strain A/chicken/Yamaguchi/7/2004 (H5N1) determines its replication potential in pigs. J Virol (2008) 1.36
Rapid and simple detection of Ebola virus by reverse transcription-loop-mediated isothermal amplification. J Virol Methods (2006) 1.35
Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection. Antimicrob Agents Chemother (2010) 1.33
Immunogenicity and protective efficacy of replication-incompetent influenza virus-like particles. J Virol (2002) 1.30
Interregional transmission of the internal protein genes of H2 influenza virus in migratory ducks from North America to Eurasia. Virus Genes (2004) 1.28
Molecular evolutionary analysis of the influenza A(H1N1)pdm, May-September, 2009: temporal and spatial spreading profile of the viruses in Japan. PLoS One (2010) 1.28
Discussions and decisions of the 2012–2014 International Committee on Taxonomy of Viruses (ICTV) Filoviridae Study Group, January 2012–June 2013. Arch Virol (2014) 1.27
Genetically destined potentials for N-linked glycosylation of influenza virus hemagglutinin. Virology (2008) 1.23
Molecular characterization of the hemagglutinin and neuraminidase genes of H5N1 influenza A viruses isolated from poultry in Vietnam from 2004 to 2005. J Vet Med Sci (2006) 1.23
Early [18F]fluorodeoxyglucose positron emission tomography at two days of gefitinib treatment predicts clinical outcome in patients with adenocarcinoma of the lung. Clin Cancer Res (2011) 1.22
Heterosubtypic antibody recognition of the influenza virus hemagglutinin receptor binding site enhanced by avidity. Proc Natl Acad Sci U S A (2012) 1.22
Serological evidence of transmission of human influenza A and B viruses to Caspian seals (Phoca caspica). Microbiol Immunol (2002) 1.21
Oseltamivir-resistant influenza viruses A (H1N1) during 2007-2009 influenza seasons, Japan. Emerg Infect Dis (2010) 1.21
A p38 MAPK inhibitor, FR-167653, ameliorates murine bleomycin-induced pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol (2002) 1.20
Involvement of extracellular signal-regulated kinase and p38 in human diabetic nephropathy. Am J Kidney Dis (2005) 1.19
H9N2 influenza viruses prevalent in poultry in China are phylogenetically distinct from A/quail/Hong Kong/G1/97 presumed to be the donor of the internal protein genes of the H5N1 Hong Kong/97 virus. Avian Pathol (2003) 1.19
Development of vaccine strains of H5 and H7 influenza viruses. Jpn J Vet Res (2008) 1.18
Intravenous peramivir for treatment of influenza A and B virus infection in high-risk patients. Antimicrob Agents Chemother (2011) 1.16
Virus nomenclature below the species level: a standardized nomenclature for laboratory animal-adapted strains and variants of viruses assigned to the family Filoviridae. Arch Virol (2013) 1.16
Isolation and characterization of potentially pathogenic H5N2 influenza virus from a chicken in Taiwan in 2008. Avian Dis (2010) 1.13
Reintroduction of H5N1 highly pathogenic avian influenza virus by migratory water birds, causing poultry outbreaks in the 2010-2011 winter season in Japan. J Gen Virol (2011) 1.13
Phase III randomized, double-blind study comparing single-dose intravenous peramivir with oral oseltamivir in patients with seasonal influenza virus infection. Antimicrob Agents Chemother (2011) 1.12
Monitoring and characterization of oseltamivir-resistant pandemic (H1N1) 2009 virus, Japan, 2009-2010. Emerg Infect Dis (2011) 1.12
Virus nomenclature below the species level: a standardized nomenclature for filovirus strains and variants rescued from cDNA. Arch Virol (2013) 1.10
Seroepidemiological evidence of avian H4, H5, and H9 influenza A virus transmission to pigs in southeastern China. Vet Microbiol (2002) 1.09
Subcutaneous hematoma due to frequent insulin injections in a single site. Intern Med (2004) 1.08
Nucleocapsid-like structures of Ebola virus reconstructed using electron tomography. J Vet Med Sci (2005) 1.06
Novel arenavirus, Zambia. Emerg Infect Dis (2011) 1.06
Sustained interleukin-6 signalling leads to the development of lymphoid organ-like structures in the lung. J Pathol (2003) 1.05
A novel Ebola virus expressing luciferase allows for rapid and quantitative testing of antivirals. Antiviral Res (2013) 1.04
Single immunization with a monovalent vesicular stomatitis virus-based vaccine protects nonhuman primates against heterologous challenge with Bundibugyo ebolavirus. J Infect Dis (2011) 1.03
Involvement of endothelial apoptosis underlying chronic obstructive pulmonary disease-like phenotype in adiponectin-null mice: implications for therapy. Am J Respir Crit Care Med (2011) 1.02
Antibody-dependent enhancement of Marburg virus infection. J Infect Dis (2011) 1.02
Detection of all known filovirus species by reverse transcription-polymerase chain reaction using a primer set specific for the viral nucleoprotein gene. J Virol Methods (2010) 1.01
Pathogenicity of H5N1 influenza A viruses isolated in Vietnam between late 2003 and 2005. J Vet Med Sci (2006) 1.01